MTM Investment Management LLC Buys Shares of 180 Thermo Fisher Scientific Inc. $TMO

MTM Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 180 shares of the medical research company’s stock, valued at approximately $73,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CBIZ Investment Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific during the first quarter valued at approximately $31,000. DiNuzzo Private Wealth Inc. raised its holdings in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares during the period. Finally, HighMark Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after buying an additional 45 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 1,058 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the completion of the sale, the vice president owned 13,087 shares in the company, valued at $7,698,558.62. This represents a 7.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 52,341 shares of company stock worth $29,204,998 in the last 90 days. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Down 0.2%

Thermo Fisher Scientific stock opened at $579.12 on Monday. The company has a market cap of $217.58 billion, a price-to-earnings ratio of 33.46, a P/E/G ratio of 3.27 and a beta of 0.82. The firm has a 50-day moving average of $527.90 and a 200-day moving average of $468.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has initiated a share repurchase program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Analysts Set New Price Targets

A number of research firms have issued reports on TMO. TD Cowen increased their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 28th. William Blair began coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating for the company. Finally, Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.